T17	Exp 105 107	We
T18	Exp 133 137	that
T19	Exp 268 272	that
T20	Exp 305 310	which
T21	Exp 138 155	the T lymphocytes
T22	Exp 222 239	the transcription
T23	Exp 505 507	we
T24	Exp 391 401	the defect
T25	Exp 405 416	the patient
T26	Exp 474 503	the affected lymphokine genes
T27	Exp 517 528	the ability
T28	Exp 553 564	the patient
T29	Exp 618 639	the regulatory region
T30	Exp 799 914	activated T cells (NF-AT) to its response element in the IL2 enhancer and to an NF-AT-like response element present
T31	Exp 762 773	the binding
T32	Exp 777 795	the nuclear factor
T33	Exp 918 934	the IL4 enhancer
T34	Exp 1043 1045	we
T35	Exp 970 1005	the abnormal NF-AT binding activity
T36	Exp 1119 1136	the reporter gene
T37	Exp 1193 1204	the control
T38	Exp 1208 1240	the entire IL2 regulatory region
T39	Exp 1318 1343	the IL2 regulatory region
T40	Exp 1364 1386	the NF-AT-binding site
T41	Exp 1409 1420	the patient
T42	Exp 1502 1520	the OCT-1 proximal
T43	Exp 1606 1610	that
T44	Exp 1663 1697	the multiple lymphokine deficiency
T45	Exp 1583 1596	These results
T46	Exp 1701 1713	this patient
R4	Coref Anaphora:T19 Antecedent:T47
T48	SPAN 281 303	IL2, IL3, IL4, and IL5
R5	Coref Anaphora:T20 Antecedent:T48
R6	Coref Anaphora:T30 Antecedent:T32
T1	Protein 281 284	IL2
T2	Protein 286 289	IL3
T3	Protein 291 294	IL4
T4	Protein 300 303	IL5
T5	Protein 643 646	IL2
T6	Protein 699 704	OCT-1
T7	Protein 856 859	IL2
T8	Protein 922 925	IL4
T9	Protein 1146 1180	chloramphenicol acetyl transferase
T10	Protein 1182 1185	CAT
T11	Protein 1219 1222	IL2
T12	Protein 1291 1294	CAT
T13	Protein 1322 1325	IL2
T14	Protein 1456 1459	CAT
T15	Protein 1506 1511	OCT-1
T47	Exp 243 267	several lymphokine genes
